This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Plan afoot to merge 3 Delhi hospitals into single 'super medical hub'

In a revolutionary move for healthcare in Delhi, officials are consolidating Guru Teg Bahadur Hospital, the Delhi State Cancer Institute, and Rajiv Gandhi Super Speciality Hospital into a formidable medical hub. This initiative is not just about maximizing efficiency; it’s about reimagining patient care with cutting-edge resources and comprehensive services at their fingertips.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tQVsLDR
via IFTTT

Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

The rise of GLP-1 weight-loss drugs such as Ozempic is posing a challenge to the fitness industry, with cheaper generic versions expected to enter India soon. While some fear this could lead to a decline in gym memberships, others see it as an opportunity to offer specialised training and integrated wellness programmes to support people using these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/C0UBNkr
via IFTTT

Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

A groundbreaking ceremony led by Union Minister Jitendra Singh has marked the start of a new Rs 600 crore pharmaceutical manufacturing plant in Kathua. This state-of-the-art facility will specialise in producing Amino Cephalosporanic Acid, a vital component of antibiotics. With this investment, India is set to bolster its pharmaceutical sector and lessen dependence on foreign imports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yeDE8hu
via IFTTT

West Asia war hits medical tourism: Overseas patient flow to Indian hospitals drops up to 75%

Israel-Iran war: Indian hospitals face a sharp decline in international patients. The ongoing conflict has disrupted travel, causing revenue losses. Hospitals report a 50% to 75% fall in overseas patient flows. This situation is prompting a shift towards attracting patients from Southeast Asia, Africa, and Central Asia. Recovery depends on regional stability and travel confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K07jhvu
via IFTTT

Ambuja Neotia Group to develop over Rs 700 cr integrated healthcare and hospitality project in Guwahati

Ambuja Neotia Group will build a large integrated healthcare and hospitality project in Guwahati. The Rs 700 crore investment will include a 300-bed multi-speciality hospital and a 4+ star hotel. This initiative aims to boost the region's healthcare infrastructure and economy. The project is expected to create thousands of jobs. It marks the group's second healthcare venture in Assam.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xielzBA
via IFTTT

'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

Bayer's CEO Bill Anderson believes India can become a top pharmaceutical market. He highlights the need for supportive policy frameworks, including stronger intellectual property protection. This will attract investment in cutting-edge drugs. India's young population and technological leadership offer significant opportunities. Bayer is investing in innovation centers in Bengaluru, leveraging Indian talent for global missions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kN8cZl1
via IFTTT

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT